Sold as Propulsid, Propulsid Quicksolv. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 3 applications for Cisapride Monohydrate (sold as Propulsid, Propulsid Quicksolv), first approved Jul 29, 1993, with 0 new uses approved and 0 published complete response letters.
| Jul 29, 1993 | PropulsidNDA 20210 · New molecular entity | Janssen Pharms | 25 | Discontinued |
| Sep 15, 1995 | PropulsidNDA 20398 · New dosage form | Janssen Pharms | 16 | Discontinued |
| Nov 7, 1997 | Propulsid QuicksolvNDA 20767 · New dosage form | Janssen Pharma | 9 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
